AstraZeneca expects Covid-19 vaccine capacity of 200 million a month by April
AstraZeneca expects COVID-19 vaccine capacity of 200 million a month by April
LONDON (Reuters) – AstraZeneca expects to produce more than 100 million doses of its COVID-19 vaccine – developed with Oxford University – this month, ramping up to more than 200 million a month by April, Chief Executive Pascal Soriot said on Thursday.
FILE PHOTO: The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease (COVID-19) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron/File Photo
Mene Pangalos, head of BioPharmaceuticals R&D at the British drugmaker earlier said the company expects much-anticipated data for the late-stage U.S. trial of its vaccine before the end of March.
A read-out on data is “only weeks away”, he said on a media call after release of the company’s 2020 results.
Reporting by Pushkala Aripaka and Ludwig Burger; Writing by Josephine Mason; Editing by David Goodman
Our Standards: The Thomson Reuters Trust Principles.
Reuters source:
